🇺🇸 FDA
Patent

US 11253522

Cancer treatment targeted to tumor adaptive responses to protein synthesis stress

granted A61KA61K31/519A61K45/06

Quick answer

US patent 11253522 (Cancer treatment targeted to tumor adaptive responses to protein synthesis stress) held by The Regents of the University of California expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Feb 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
6
CPC classes
A61K, A61K31/519, A61K45/06, A61P, A61P35/02